News

The award will support Erb’s drug discovery platform to identify novel cancer therapies.

Blackmond joins a long line of respected scholars defined as being “Nunquam otiosus,” or “never idle,” the motto of the academy.

The program helps prepare and support talented new investigators at pivotal moments in their career.

Huntington’s disease progression involves a promoter of inflammation and autophagy, the cellular housekeeping process, a new study finds.  

The Board of Overseers, one of two governing boards at Scripps Research, provides expertise and leadership to advance the institute’s mission.

The rich data stored in electronic medical records may offer clues to better care for those diagnosed with coronavirus disease.

Some common strains of influenza are able to mutate to evade some of the broad-acting antibodies that could be elicited by a universal flu vaccine. 

With an initial focus on screening local healthcare workers and first responders, the study seeks to understand the prevalence of coronavirus infections in the community.

Promoting a healthy gut microbiome may be a powerful strategy for lowering cholesterol and other heart attack risk factors.

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against the coronavirus that causes the disease.

Cravatt is recognized for major technical advances in activity-based protein profiling, which is used to find potential new targets and drug candidates for cancer treatment.

A tiny genetic mutation to the virus that causes COVID-19 leads to a significant change in the virus’ ability to infect cells, according to new research from Hyeryun Choe, PhD, and Michael Farzan, PhD.

Scripps Research is collaborating with top computational scientists at Johns Hopkins University and UCLA.

On behalf of the institute, the leadership team at Scripps Research voices its recommitment to expanding diversity and inclusion across its campuses.

Analysis of data from 16 groups of COVID-19 patients suggest “silent” carriers may exacerbate efforts to stop spread of the disease

Scientists discovered a way to enhance the activity of an enzyme long suspected of playing a role in metabolism. In a study involving mice, the compound reversed signs of diabetes.

Response to essay published in Angewandte Chemie.

The drug, developed at Scripps Research, recently gained U.S. and European regulatory approval for the treatment of multiple sclerosis. It is also being studied for Crohn’s disease.

The news comes less than two months after the therapy gained approval from the U.S. Food and Drug Administration. Ozanimod is also in advanced clinical development for moderate-to-severe ulcerative colitis and Crohn’s disease.

In experiments on human 'mini-brains,' the drug preserved nerve connections that are lost to Alzheimer’s. The drug is also being evaluated for COVID-19, as it is known to inhibit viral activity.

How does general anesthesia cause loss of consciousness? Despite its 175-year-history of use by the U.S. medical system, science has been unable to definitively answer that question, until now.

Patapoutian, who made transformative discoveries about proteins that sense pressure, becomes the first Scripps Research scientist to win the Kavli Prize. 

Even though the coronaviruses that cause SARS and COVID-19 are closely related and infect cells the same way, they aren’t cross-protective in cell culture experiments.